Learning Objectives:

  1. To discuss the pharmacologic differences of GLP1 products for obesity
  2. To discuss efficacy of different GLP1 products in bariatric and non-bariatric populations
  3. To debate use of medications with cardiovascular implications (DOAC, GLP-1, SGLT2) in the post-bariatric surgery population

8:00am GLP-1 Considerations for the Bariatric Surgical Practice
Scott V Monte, PharmD
8:30am Medications with Cardiovascular Implications after Bariatric Surgery
Nicholas Norgard, PharmD
9:15am Debate / Q&A Session
9:30am Adjourn